Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Patient Preference and Adherence
- Vol. 14, 817-827
- https://doi.org/10.2147/PPA.S242957
Abstract
Purpose: Allergen immunotherapy (AIT), when continued for 3 years, is the only diseasemodifying treatment for AR and asthma. Adherence is a key to ensure effectiveness, and poor adherence is a contraindication for AIT. The objective of this study was to evaluate realworld adherence to AIT with subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) preparations in patients allergic to grass or tree pollen. The impact of AIT on the consumption of asthma and rhinitis medication was also analyzed. Patients and Methods: In this retrospective cohort analysis of a German longitudinal prescription database, the adherence of a grass and tree pollen allergoid was examined and compared to two sublingual AIT tablets/drops. Patients receiving grass or tree allergen-specific immunotherapy prescriptions were compared with non-AIT patients receiving symptomatic allergic rhinitis (AR) and asthma prescriptions. The study endpoints included therapy adherence, AR progression, and asthma progression. Multivariate regression analyses were used to estimate the effects of SCIT or SLIT, adjusting for variables related to demographics and prescriptions. Results: SCIT adherence was 60.1-61.8% at 2 years and 35.0-37.5% at 3 years for the two allergens. SLIT adherence was distinctly lower (29.5-36.5% and 9.6-18.2%, respectively). Adherence in children was higher compared to adolescents or adults. All products were highly efficacious at reducing symptomatic AR medication consumption. SCIT also reduced asthma medication use for both allergens, whereas for SLIT these results were significant only for grasses but not trees. Conclusion: Subcutaneous AIT in a real-world setting achieved significantly higher adherence rates compared to sublingual administration. SCIT reduced the use of rhinitis and asthma medication significantly for both allergens, while SLIT reduced the use of rhinitis medication for both allergens and the use of asthma medication for grasses only.This publication has 48 references indexed in Scilit:
- Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needsJournal of Allergy and Clinical Immunology, 2012
- Allergic rhinitis is associated with poor asthma control in children with asthmaThorax, 2012
- EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapyClinical and Translational Allergy, 2012
- Immunotherapy for allergic rhinitisClinical & Experimental Allergy, 2011
- Sublingual immunotherapy: adherence based on timing and monitoring control visitsAllergy, 2010
- Evidence of adherence to allergen-specific immunotherapyCurrent Opinion in Allergy and Clinical Immunology, 2009
- Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part IValue in Health, 2009
- Establishing the incidence and prevalence of clinician‐diagnosed allergic conditions in children and adolescents using routinely collected data from general practicesClinical & Experimental Allergy, 2009
- Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey IAllergy, 2007
- Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status QuestionnaireJournal of Allergy and Clinical Immunology, 1994